Abstract: The present invention relates to a bacterial strain having a genetic homology of at least 95% to one or more of the bacterial strains selected from the group consisting of: Weissella viridescens LB10G, which is deposited as DSM 32906; Lactobacillus paracasei LB113R, which is deposited as DSM 32907; Lactobacillus plantarum LB244R, which is deposited as DSM 32996; Lactobacillus paracasei LB116R, which is deposited as DSM 32908; Enterococcus faecium LB276R, which is deposited as DSM 32997; Lactobacillus plantarum LB316R, which is deposited as DSM 33091; Leuconostoc mesenteriodes LB341R; Leuconostoc mesenteriodes LB349R, which is deposited as DSM 33093; Lactobacillus plantarum LB356R, which is deposited as DSM 33094; Lactobacillus plantarum LB312R, which is deposited as DSM 33098.

Abstract: A composition for treating or preventing COVID-19 infection is described. The composition includes attenuated Measles virus particles; attenuated Mumps virus particles; attenuated Rubella II virus particles; scorpion antivenom; and a pharmaceutically acceptable carrier. The composition can be used in a method of treating COVID-19 infection in a subject, and can also be used in a method of vaccinating a subject to decrease the risk or severity of infection by COVID-19.

Abstract: A pseudorabies virus (PRV) or a modified form thereof, or a genome sequence or a cDNA sequence containing the PRV or the modified form thereof, or nucleic acid molecules of a complementary sequence of the cDNA sequence, for treating tumors of subjects and/or reducing or inhibiting tumor recurrence, and for preparation of a pharmaceutical composition used for treating the tumors of the subjects and/or reducing or inhibiting the tumor recurrence. A method for treating tumors and/or reducing or inhibiting tumor recurrence, comprising a step of administering, on a subject having a need, the PRV or the modified form thereof, or nucleic acid molecules of the genome sequence containing the PRV or the modified form thereof.

Abstract: Use of an olive oil milling by-product (Alperujo or Olive Pomace) for the co-processing and co-extraction of natural compounds from medicinal and aromatic plants including cannabis, fruits and agricultural waste, algae and other microorganisms. Separation and stabilization of fractions containing either hydrophilic or liposoluble compounds.

Abstract: Novel plant products customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.

Abstract: Novel plant products customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.

Abstract: The present disclosure provides for a method of treating a bacterial colonization or primary or secondary bacterial infection of an underlying skin disorder in a subject via the topical administration of a pharmaceutical composition comprising a therapeutically effective amount of an extract of the Croton lechleri tree. Additionally the present disclosure provides for a method of treating a bacterial colonization or primary or secondary bacterial infection of the nasal mucosa in a subject via the nasal administration of a pharmaceutical composition comprising a therapeutically effective amount of an extract of the Croton lechleri tree. Also provided are details of studies on the effectiveness of an extract of the Croton lechleri tree on bacterial pathogens.

Abstract: The present disclosure provides a system for modulating jaw pain and bruxism. The system includes a tube having a composition formulated as a topical balm comprising a botanical formulation and a topically acceptable carrier and a dispensing tube having an applicator tip.

Abstract: A composition, containing a pepper component, a curcumin-cyclodextrin mixture and a mixture of fruits, vegetables and spices.

Abstract: A care composition includes an extract from the stems and/or the leaves of a sweet potato, and/or a yam-bean, and/or a yam together with an ion solution. The care composition has a salinity of 0.9%-4% (W/W) and contains less than 0.3% (W/W) of sodium, 0.3%-1% (W/W) of magnesium, and 0.02%-0.2% (W/W) of potassium.

Abstract: A moisturizing composition, the composition comprising a sufficient amount of extra-virgin coconut oil, a sufficient amount of aloe barbadensis, and a sufficient amount of vitamin E oil. The composition is provided as a cream, which may be applied to a body cavity, such as within and/or around the vagina.

Abstract: The present disclosure provides a combined plant extract for getting rid of mites and acne obtained by ultrasound-assisted water extraction and alcohol precipitation of at least one of Nepeta cataria, bamboo, celery seeds, and orange peels. The preparation method of the present disclosure is simple and easy to operate, where extraction from effective parts of raw materials can be carried out sufficiently. The combined plant extract of the present disclosure was subjected to in vitro mite elimination experiments, and the results showed that it had excellent effects in getting rid of mites.

Abstract: The invention pertains to liposomes containing an oil-in-water emulsion of a selected combination of at least ten different essential plant oils produced with phospholipids found in human membranes and methods for treating respiratory diseases, disorders or conditions by administering the liposomes into the nose and respiratory system.

Abstract: The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.

Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.

Abstract: The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide.

Abstract: The present disclosure relates to a method of treating sensorineural deafness. The disclosure provides a method of treating sensorineural deafness in a mammalian subject (e.g., human) in need thereof. The method comprises administering to a subject having a mutation in a CLDN9 gene a composition that comprises a polynucleotide that encodes a CLDN9 peptide, a CLDN9 peptide, an agent that blocks expression of a mutant CLDN9 gene, an agent that corrects the mutation in the CLDN9 gene.

Abstract: The invention relates to the use of an isolated peptide of 10 to 32 amino acid residues in length for the treatment of neural injury, wherein the isolated peptide comprises at least 10 to 22 arginine residues. The peptide may be a poly-arg sequence or an arginine-rich peptide.

Abstract: This disclosure provides for the application of a multi-disciplinary analysis of information sources to draw novel conclusions that result in new methods to diagnose, prevent or treat COVID-19. COVID-19 appears to be an extremely complex disease, encompassing three critical aspects at least: a viral infection, an immune system disorder, and a cardiovascular/pulmonary/renal disease with significant coagulation system dysregulation. This disclosure principally focuses on the design and methods of use of a combinatorial apparatus that addresses critical needs to treat patients with COVID-19, especially those at high risk of, or experiencing, adverse effects of COVID-19 infection, including but not limited to kidney function support, supplemental oxygen administration, correction of cardiovascular dysfunction, and removal or modification of deleterious molecules or agents from or in a patient's blood, including virus particles or molecular components thereof.

Abstract: Described herein are methods for treating a subject having or at risk of developing a neurocognitive disorder, such as frontotemporal lobar degeneration or neuronal ceroid lipofuscinosis, by administering cells that contain a transgene encoding a progranulin (PGRN) or a granulin (GRN) or cells that express the PGRN or the GRN to the subject. Also disclosed are compositions comprising cells containing the transgene encoding the PGRN or the GRN.

Abstract: Compositions and methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of HB-EGF activity.

Abstract: The present invention discloses application of FGF21 in the preparation of medicines for treating colorectal cancer, and belongs to the technical field of medicine. The FGF21 protein provided by the present invention is a secreted protein composed of about 210 amino acids. The present invention found that FGF21 has the effect of treating colorectal tumors for the first time. It is proved by cytology and animal experiments that FGF21 can inhibit the proliferation, invasion and migration of colorectal tumor cell lines; can significantly reduce the size of tumor lesions in mouse models. The medicines prepared from FGF21 as the active ingredient for treating colorectal cancer has good safety and long duration of drug action, while it protects organs from damage and has the effect of improving lipid metabolism disorders.

Abstract: Provided is use of IL-15 protein complex joint PD-L1 antibody for treating tumor diseases.

Abstract: Disclosed are a VIP gene expressing microorganism, a composition or a kit for preventing or treating a disorder causing gastrointestinal tract damage comprising the same, and a method for preventing or treating a disorder causing gastrointestinal tract damage using the same.

Abstract: The present invention relates to compositions and methods for treating neurodegenerative conditions using GLP-1r agonists. In certain embodiments, long-acting GLP-1r agonists have neuroprotective and disease modifying effects on the central nervous system.

Abstract: The disclosure provides for compounds, compositions, and methods of use thereof for treating diabetes (e.g., type 1 diabetes, type 2 diabetes). In some aspects, methods comprise administering first, second, third, fourth, and fifth daily doses of insulin-like growth factor 2 (“IGF-2”) or a variant thereof to the subject at respective first, second, third, fourth, and fifth different times, wherein each of the daily doses comprises at least 65 ?g of IGF-2. In other aspects, compounds, compositions, and methods containing IGF-2 or variants thereof are used for treating a disorder in a patient in need thereof, such as type 1 or type 2 diabetes.

Abstract: The present disclosure is directed to methods of increasing remyelination in subjects in need thereof.

Abstract: The present invention relates to a compound decreasing the concentration of 2-hydroxy-glutarate (2HG) in a subject for use in treating, preventing, and/or preventing progression of cardiac remodeling, in particular cardiomyopathy and/or heart failure and to viral particles, compositions, uses and methods related thereto.

Abstract: Glucose oxidase and further compositions are described. The glucose oxidase compositions have glucose oxidase and at least one ingredient selected from one or more of carbohydrate (e.g. dietary fibre or saccharide), polyol or sugar alcohol while further compositions are sweeteners, food, compositions for fortification of food, nutraceuticals and pharmaceuticals. The compositions incorporate low glycemic index nutritive compound of glycemic index less than 70, preferably less than 50, and are in the form of powders, granules, crystalline compositions, flours, pills, tablets, capsules, pellets, powder for oral suspensions, gels, liquid solutions and suspensions, and sterile preparations.

Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.

Abstract: The invention concerns an isolated peptide and variants thereof, and therapeutic uses thereof. In particular, such peptides have anti-tumor activity with high selectivity, efficacy and low toxicity. Pharmaceutical compositions comprising the peptides of the invention are also described.

Abstract: Provided herein are methods and compositions comprising constructs that include two or more truncated T3SS bacterial effector polypeptides. Also provided are pharmaceutical compositions comprising the constructs and methods of treatment of inflammatory disorders based on administering such constructs.

Abstract: Killer toxins that may have activity against organisms, such as pathogenic organisms, and organisms that express the killer toxins are disclosed herein. The organism may be a recombinant organism or it may endogenously express a killer toxin. In some embodiments, a composition comprises one or more organisms, such as one or more Saccharomyces yeasts, and/or one or more killer toxins, such as K1, K2, and/or K1L toxins. In other embodiments, compositions comprise nucleic acids, vectors, host cells, or combinations thereof, comprising one or more killer toxins. Compositions can include one or more additional components, such as, but not limited to, a buffer, carrier, adjuvant, additional therapeutic, or combinations thereof. Kits that comprise one or more organisms and/or killer toxins are described. Uses of the organisms and/or killer toxins can include administration to a subject to treat an infection by one or more yeasts, such as Candida glabrata.

Abstract: Described herein are BRCA1 modulating compounds and formulations thereof. In some aspects, the BRCA1 modulating compound is a deubiquitinase. In some aspects, the BRCA1 modulating compound is a deubiquitinase inhibitor. as Also described herein are methods of treating a subject in need thereof with a BRCA1 modulating compound or formulation thereof. In some aspects, the subject in need thereof can have a cancer. In some aspects, the subject in need thereof has one or more BRCA1 mutations.

Abstract: The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent, agitating and shearing said suspension in a high shear mixing reactor, adding water to allow particles to agglomerate, allowing the non-aqueous solvent to evaporate, drying and sieving the composition; and thus forming the powdered hemostatic composition.

Abstract: The present invention relates to the use of elafin for the treatment and/or prevention of diseases or disorders associated with an increase in troponin levels, which are non elastase dependent. The present invention in a preferred embodiment relates to a method and composition, using elafin, for protecting the heart muscle or other muscles from damage induced by abnormal blood flow and/or inflammation, which may result from, for example, a heart infarction. The present invention additionally or concomitantly relates to the use of elafin for the treatment and/or prevention of disorders or diseases which are associated with a rise in the level of troponin I and/or T.

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to an anticancer neoepitope composition comprising polynucleotides or polypeptides, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine. The anticancer neoepitope composition comprising a DNA polynucleotide comprising a nucleotide sequence encoding an antigenic unit comprising from 2 to 50 antigenic subunits, each subunit comprising at least a part of a cancer neoepitope sequence and a linker and a terminal antigenic subunit comprising at least a part of a cancer neoepitope sequence.

Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.

Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.

Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen are disclosed. Methods of treating a subject with a MUC16-expressing tumor and methods of preventing a MUC16-expressing tumor are disclosed. Modified consensus MUC16 antigen is disclosed.

Abstract: Disclosed are immunization antigens that have been glyco-engineered to include non-native glycosylation patterns with a view to enhance their properties as antigens for use in such areas as vaccination and antibody production. Also disclosed are to means and methods for producing the glycomodified antigens as well of methods and uses of the glycomodified antigens.

Abstract: The present invention provides a combination of an agonist of stimulator of interferon response cGAMP interactor 1 (STING) and a vaccine including specific antigens or antigenic epitopes, namely, a complex comprising a cell penetrating peptide, at least one antigen or antigenic epitope, and a TLR peptide agonist. Such a combination is particularly useful in medicine, in particular in the prevention and/or treatment of cancer. Moreover, the present invention also provides compositions, such as a pharmaceutical compositions and vaccines, which are useful, for example, in the prevention and/or treatment of cancer.

Abstract: A polymeric nanoparticle is disclosed which comprises: (i) at least one disease-associated antigen which is capable of producing a T-cell response, wherein the disease-associated antigen is encapsulated in the nanoparticle; (ii) at least one adjuvant; and (iii) a dendritic cell targeting moiety which is attached to the outer surface of the nanoparticle. Use of the nanoparticle for treating diseases associated with abnormal cell growth or an infection is also disclosed.

Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I—restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.

Abstract: Immunogenic proteins from Moraxella catharrhalis as well as nucleic acids, vectors and transformed cells useful for expression of the proteins. Methods for prophylaxis of infection with Moraxella catharrhalis using the proteins, nucleic acids, vectors or transformed cells.

Abstract: The present invention is directed to novel immunogenic compositions that protect swine from disease caused by porcine epidemic diarrhea virus (PEDV). The compositions of the invention provide virus-like particles (VLPs) whose effectiveness is enhanced by the selection of preferred adjuvants.

Abstract: Compositions and methods are described for inducing an immune response against an immunogen in humans. The induced immune response is obtained by administering a heterologous prime-boost combination of an in vitro transcribed (IVT) self-replicating RNA (repRNA) and an adenovirus vector. The compositions and methods can be used to provide a protective immunity against a disease, such as a viral infection or a cancer, in humans.

Abstract: Aspects of the invention concern a composition or a kit-of-parts comprising i) a virus which is a member of the Reoviridae family and ii) sialic acid and/or a molecule comprising at least one sialic acid moiety, as well therapeutic applications thereof.

Abstract: A novel vaccine antigen for prevention of Respiratory Syncytial Virus (RSV) infection is created which surpasses conventional vaccines comprising as an antigen RSV F protein alone in view of efficacy and/or safety. A vaccine is prepared which comprises as an antigen a RSV F/G chimeric protein wherein a portion of RSV F protein as a basic structure is replaced with a whole or a portion of Conserved Central Domain sequence of RSV G protein or wherein a whole or a portion of Conserved Central Domain sequence of RSV G is added to the basic structure. As a result of assessment of both efficacy and safety, a vaccine comprising as an antigen the F/G chimeric protein of the present invention confirmed to be more excellent than a vaccine comprising as an antigen RSV F protein alone in view of efficacy and/or safety.